A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

Trial Details

NCT ID
NCT06055439
Phase
PHASE1 / PHASE2
Sponsor
Chimeric Therapeutics
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CHM-2101 CAR-T cells
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Documented informed consent of the participant and/or legally authorized representative.
  • Confirmed histologic diagnosis of one of the following solid tumors of GI origin:
  • Gastric adenocarcinoma Note: for gastric adenocarcinoma patients only, central laboratory confirmation of CDH17+ tumor expression is required.
  • Colon and/or rectal adenocarcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →